Literature DB >> 12460196

Opposing roles of activator protein-1 and CCAAT/enhancer binding protein beta in the regulation of inducible granulysin gene expression in a human monocytic cell line, THP-1.

Yutaka Kida1, Takashi Shimizu, Koichi Kuwano.   

Abstract

We previously reported that inducible granulysin gene expression in a human monocytic cell line, THP-1 is dominantly dependent on transcription factor activator protein-1 (AP-1). Here, we further examined the precise regulatory mechanisms underlying granulysin gene expression using THP-1 cells treated with Acholeplasma laidlawii. Transfection of reporter gene constructs into THP-1 cells indicated that the presence of a positive regulatory element(s) is located from -329 to -85 base pairs, containing two distinct AP-1 binding sites and one nuclear factor-kappaB (NF-kappaB) binding site. Deletion or mutation of the NF-kappaB binding site failed to affect inducible promoter activity, whereas deletion or mutation of both the AP-1 binding sites abrogated the promoter activity. Interestingly, deletion of the putative CCAAT/enhancer binding protein beta (C/EBPbeta) binding site upstream of the positive regulatory element induced the augmentation of granulysin promoter activity. Electrophoretic mobility shift assays demonstrated that nuclear extract prepared from A. laidlawii-treated THP-1 cells generated a specific binding to oligonucleotides, including AP-1, C/EBPbeta, and NF-kappaB element. Furthermore, over-expression of liver-enriched transcriptional activator protein, a subunit of C/EBPbeta, augmented A. laidlawii-induced granulysin promoter activity, whereas over-expression of liver-enriched transcriptional inhibitory protein inhibited the promoter activity. NF-kappaB p50 homodimer had no transactivation property, although it bound to the NF-kappaB site. These results indicate that AP-1 and C/EBPbeta, but not NF-kappaB participate in the regulation of inducible granulysin gene expression in THP-1 cells. Moreover, the Toll-like receptor 2-dependent signalling pathway may be involved in A. laidlawii-induced transactivation of the granulysin promoter. Thus, these results suggest that the gene expression of granulysin in macrophages would be exquisitely regulated by positive and negative transcription factors when microbial invasion occurs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460196      PMCID: PMC1782811          DOI: 10.1046/j.1365-2567.2002.01524.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  54 in total

1.  Production of a T-cell clone which reacts with membrane proteins of Acholeplasma laidlawii.

Authors:  K Kuwano; S Ono; A Akashi; M Ohishi; H Shigematsu; S Arai
Journal:  Microbiol Immunol       Date:  1997       Impact factor: 1.955

2.  NF-kappa B: ten years after.

Authors:  P A Baeuerle; D Baltimore
Journal:  Cell       Date:  1996-10-04       Impact factor: 41.582

3.  Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins.

Authors:  S V Peña; D A Hanson; B A Carr; T J Goralski; A M Krensky
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

Review 4.  NF-kappa B: a lesson in family values.

Authors:  D Thanos; T Maniatis
Journal:  Cell       Date:  1995-02-24       Impact factor: 41.582

Review 5.  Structure, regulation and function of NF-kappa B.

Authors:  U Siebenlist; G Franzoso; K Brown
Journal:  Annu Rev Cell Biol       Date:  1994

6.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.

Authors:  R Medzhitov; P Preston-Hurlburt; C A Janeway
Journal:  Nature       Date:  1997-07-24       Impact factor: 49.962

7.  C/EBP beta regulation of the tumor necrosis factor alpha gene.

Authors:  R M Pope; A Leutz; S A Ness
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

8.  Mycoplasma arginini TUH-14 membrane lipoproteins induce production of interleukin-1, interleukin-6, and tumor necrosis factor alpha by human monocytes.

Authors:  A Herbelin; E Ruuth; D Delorme; C Michel-Herbelin; F Praz
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

Review 9.  Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety.

Authors:  J B Baseman; J G Tully
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

10.  Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration.

Authors:  P F Mühlradt; M Kiess; H Meyer; R Süssmuth; G Jung
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

View more
  5 in total

1.  Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2.

Authors:  Yutaka Kida; Hiroyoshi Inoue; Takashi Shimizu; Koichi Kuwano
Journal:  Infect Immun       Date:  2006-10-16       Impact factor: 3.441

2.  Conditional expression of liver-enriched transcriptional activator protein augments Acholeplasma laidlawii-induced granulysin gene expression in a human monocytic cell line, THP-1.

Authors:  Yutaka Kida; Takashi Shimizu; Koichi Kuwano
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

3.  Association of GNLY genetic polymorphisms with chronic liver disease in a Korean population.

Authors:  Geun-Hee Park; Kyoung-Yeon Kim; Jae Youn Cheong; Sung Won Cho; KyuBum Kwack
Journal:  DNA Cell Biol       Date:  2012-07-12       Impact factor: 3.311

4.  Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin.

Authors:  Poonam Tewary; De Yang; Gonzalo de la Rosa; Yana Li; Michael W Finn; Alan M Krensky; Carol Clayberger; Joost J Oppenheim
Journal:  Blood       Date:  2010-07-21       Impact factor: 22.113

5.  Expression and secretion of cathelicidin LL-37 in human epithelial cells after infection by Mycobacterium bovis Bacillus Calmette-Guérin.

Authors:  Patricia Méndez-Samperio; Elena Miranda; Artemisa Trejo
Journal:  Clin Vaccine Immunol       Date:  2008-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.